• 1
    Paquette RL. Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Williston Park) 2002; 16( suppl 10): 153161.
  • 2
    Stevens W, Koene H, Zwaginga JJ et al. Chronic Idiopathic Thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med 2006; 64: 356363.
  • 3
    Tijssen MR, van der Schoot CE, Voermans C et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev 2006; 20: 283293.
  • 4
    Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 10551065.
  • 5
    Bordin G, Ballare M, Zigrossi P et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995; 13( suppl 13): S39S43.
  • 6
    Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: The primary regulator of platelet production. Oncogene 2002; 21: 33593367.
  • 7
    Kuter DJ, Begley CG. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002; 100: 34573469.
  • 8
    Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995; 374: 4852.
  • 9
    Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999; 274: 1348013484.
  • 10
    Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis. Blood 1999; 94: 12731282.
  • 11
    Bartley TD, Bogenberger J, Hunt P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 11171124.
  • 12
    de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533538.
  • 13
    Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568571.
  • 14
    Lok S, Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565568.
  • 15
    Wendling F, Maraskovsky E, Debili N et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571574.
  • 16
    Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 32413248.
  • 17
    Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33: 8593.
  • 18
    Duffy KJ, Darcy MG, Delorme E et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001; 44: 37303745.
  • 19
    Duffy KJ, Shaw AN, Delorme E et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002; 45: 35733575.
  • 20
    Duffy KJ, Price AT, Delorme E et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002; 45: 35763578.
  • 21
    Erickson-Miller C, DeLorme E, Iskandar M et al. Species specificity and receptor domain interaction of a small molecule TpoR agonist. Blood 2004; 104: 2909.
  • 22
    Nakamura T, Miyakawa Y, Miyamura A et al. A novel nonpetidyl human c-Mpl activator stimulates human megakaryocytopoiesis and thrombosis. Blood 2006; 107: 43004307.
  • 23
    Kim M-J, Park SH, Opella SJ et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007; 282: 1425314261.
  • 24
    Erhardt J, Tapley P, Erickson-Miller, C. A low molecular weight, orally active TpoR agonist, SB-497115, does not prime platelets for activation or agonist-induced aggregation in vitro. Exper Hematol 2005; 33(1 suppl ): 365.
  • 25
    Jenkins JM, Williams D, Deng Y et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 47394741.
  • 26
    Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511521.
  • 27
    Harker LA, Roskos LK, Marzec UM et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95: 25142522.
  • 28
    Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 22372247.
  • 29
    Kantarjian HM, Giles FJ, Fenaux P et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study. J Clin Oncol 2007; 25(18 suppl ): 7032.
  • 30
    McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 22272236.
  • 31
    Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: MetcalfBW, DillonS, eds. Target Validation in Drug Discovery. Burlington, MA: Academic Press, 2007: 241254.